Curis’ (CRIS) Overweight Rating Reaffirmed at Cantor Fitzgerald

Curis (NASDAQ:CRISGet Rating)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Curis’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.80) EPS.

Curis Trading Up 1.1 %

Shares of CRIS opened at $0.79 on Wednesday. The firm’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.26. Curis has a twelve month low of $0.70 and a twelve month high of $8.50. The firm has a market capitalization of $72.50 million, a P/E ratio of -1.28 and a beta of 2.64.

Curis (NASDAQ:CRISGet Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Curis had a negative net margin of 533.89% and a negative return on equity of 68.41%. During the same quarter last year, the company earned ($0.12) EPS. Analysts predict that Curis will post -0.69 EPS for the current year.

Institutional Trading of Curis

Several large investors have recently modified their holdings of the business. Virtus ETF Advisers LLC grew its position in shares of Curis by 40.1% in the fourth quarter. Virtus ETF Advisers LLC now owns 36,911 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 10,572 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its position in shares of Curis by 40.2% in the first quarter. Dynamic Technology Lab Private Ltd now owns 40,700 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 11,660 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Curis by 53.9% in the first quarter. GSA Capital Partners LLP now owns 33,316 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 11,668 shares during the last quarter. Swiss National Bank lifted its stake in shares of Curis by 7.9% during the first quarter. Swiss National Bank now owns 162,500 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 11,900 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in shares of Curis during the first quarter valued at approximately $32,000. 47.21% of the stock is currently owned by institutional investors and hedge funds.

About Curis

(Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

See Also

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.